AblaCare
Company

Last deal

$25M

Amount

Series B

Stage

13.05.2024

Date

3

all rounds

$36.2M

Total amount

General

About Company
AblaCare provides a minimally invasive treatment to restore ovulation in women with PCOS-related infertility.

Industry

Sector :

Subsector :

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Series B

IPO status

Private

Description

AblaCare's investigative ablation technology is designed to assist the body to ovulate naturally through a one-time, durable, minimally invasive procedure done in the clinic setting under ultrasound guidance, without requiring general anesthesia. This modern approach to PCOS aims to provide patients with a more natural and less medicalised pregnancy experience, similar to IVF, but with a simpler and less invasive procedure.
Contacts

Social url